Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
April 19, 2023 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 11, 2023 07:00 ET
|
ONL Therapeutics
Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment Preclinical data in models of inherited...
DIAGNOS et l'ÉTS dévoilent un procédé permettant d’adapter les algorithmes d'apprentissage profond selon la diversité des contextes
February 28, 2023 09:00 ET
|
DIAGNOS inc.
BROSSARD, Québec, 28 févr. 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (« DIAGNOS », la « Société » ou « nous ») (Bourse de croissance TSX : ADK) (OTCQB : DGNOF) est un des leaders dans le...
DIAGNOS and ÉTS Unveil a Method to Adapt Deep Learning Algorithms According to the Diversity of Contexts
February 28, 2023 09:00 ET
|
DIAGNOS Inc.
BROSSARD, Quebec, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) is one of the leaders in early detection of critical health...
Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology
May 05, 2022 07:05 ET
|
Clearside Biomedical, Inc.
- Multiple Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing SCS Microinjector® - - Dr. Thomas Ciulla to Participate in a Panel Discussion at Retina World Congress 2022 on May 12,...
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022
April 26, 2022 16:10 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting
May 10, 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 10, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
April 23, 2021 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
Guardion's Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma
May 07, 2019 07:00 ET
|
Guardion Health Sciences, Inc.
In a recent study presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 annual meeting, treatment with Lumega-Z was associated with significant improvement in Visual Field...
ProQR to Present at Three Scientific Conferences in April
April 22, 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...